Development and Evaluation of Adeno-HTLV-III Hybrid Virus and Non-Cytopathic HTLV-III Mutant for Vaccine Use
a recombinant adeno-HIV virus and vaccinia-HIV hybrid virus. Assessment of vaccine efficacy against vaccine virus challenge includes T4/T8 ratios, HIV serology, and ability to detect infectious HIV virus in peripheral blood cells. T cell mediated immune responses will-be monitored by cytotQxic T cell activity and antigeninduced cellular proliferation. B. Background: AIDS is a recently identified disease characterised by increasing deficiencies in the body's cell mediated immune response in previously normal patients (3). A reduction in the number of helper T lymphocytes (OKT4+) is usually involved and is accompanied by multiple opportunistic infectious and/or malagancies (7). A syndrome designated AIDS related complex (ARC) has been identified in groups at risk. The dominant clinical expression in ARC is unexplained chronic lymphadenopathy or leukopenia involving a reduction in ORT4+ cells. Minor cutaneous infections, diarrhea, weight lops and fever may be associated with ARC (8). Results from research scientists in France and the United States strongly suggest that a previously unknown virus now called HIV I is the primary aetiological agent of AIDS. Western Blot analysis reveals that AIDS and ARC patients serum contains antibodies to all or some of HIV proteins (9). Chimpanzee'is the only non-human primate known to be susceptible to infection with RIV (4,5). Infected chimpanzees develop a transient severe lymphoadenopathy. Virus can be recovered from peripheral blood lymphocytes and bone marrow but not the plasma, saliva or cerebralepinal fluid (10). Although all RiV inoculated chimps remain persistently infected, a persistent decrease in TA+ cells does not develop and the chimpanzees remain clinically well (11). Preliminary experiments by Dr. Daniel Zagury indicated that Africian Green monkeys (C. aethiop ) infected with liV virus by intraperitonetal(P) njection develop viral infection. Some animals showed evidence of infection as detected by reverse transcriptase activity, ability to transmit RIV infection to peripheral blood lymphocytes and the presence of RliV genome in their peripheral blood lymphocytes. Some monkeys had a serum antibody response.o HiV. Because not all of infected animals could be shown to be infected, this model requires further characterization. When a foreign body invades the body, a variety of immune reponsesr including antibody and cytotoxic T cells, can be induced. In order to be successful, a
About this Item
- Title
- Development and Evaluation of Adeno-HTLV-III Hybrid Virus and Non-Cytopathic HTLV-III Mutant for Vaccine Use
- Author
- Lubet, Martha Turner, 1950- | Dusing-Swartz, Sandra Kay
- Canvas
- Page 4
- Publication
- 1987-10-28
- Subject terms
- reports
- Series/Folder Title
- Disease Management > AIDS Vaccines > Clinical Trials > Department of Defense (U.S.)
- Item type:
- reports
Technical Details
- Collection
- Jon Cohen AIDS Research Collection
- Link to this Item
-
https://name.umdl.umich.edu/5571095.0337.008
- Link to this scan
-
https://quod.lib.umich.edu/c/cohenaids/5571095.0337.008/11
Rights and Permissions
The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.
Related Links
IIIF
- Manifest
-
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0337.008
Cite this Item
- Full citation
-
"Development and Evaluation of Adeno-HTLV-III Hybrid Virus and Non-Cytopathic HTLV-III Mutant for Vaccine Use." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0337.008. University of Michigan Library Digital Collections. Accessed June 20, 2025.